{"filing":{"accession_number":"0001776985-26-000051","cik":"0001776985","ticker":"BNTX","company_name":"BioNTech SE","form":"6-K","filing_date":"2026-08-03","report_date":"2026-08-03","primary_document":"form6-kceoannouncement3aug.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1776985/000177698526000051/form6-kceoannouncement3aug.htm"},"events":[{"id":23008,"run_id":20828,"accession_number":"0001776985-26-000051","anchor_item_number":"EX-99.1","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"BioNTech's Supervisory Board appointed Guido Oelkers, Ph.D., to the Management Board as Chief Executive Officer, succeeding Prof. Ugur Sahin. This is a material executive appointment of a C-suite officer (CEO) at a major biopharmaceutical company, disclosed via press release on August 3, 2026, with an effective date by February 1, 2027. The appointment of a new CEO is a significant governance and leadership event that would affect a reasonable investor's assessment of the company's strategic direction and execution capability.","company_name":"BioNTech SE","ticker":"BNTX","filing_date":"2026-08-03","form":"6-K","submitted_at":null,"items":[{"id":23144,"accession_number":"0001776985-26-000051","item_number":"EX-99.1","item_title":"a991biontechannouncesappoi.htm","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"BioNTech's Supervisory Board appointed Guido Oelkers, Ph.D., to the Management Board as Chief Executive Officer, succeeding Prof. Ugur Sahin. This is a material executive appointment of a C-suite officer (CEO) at a major biopharmaceutical company, disclosed via press release on August 3, 2026, with an effective date by February 1, 2027. The appointment of a new CEO is a significant governance and leadership event that would affect a reasonable investor's assessment of the company's strategic direction and execution capability.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-03T10:55:38.543901+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":23144,"accession_number":"0001776985-26-000051","item_number":"EX-99.1","item_title":"a991biontechannouncesappoi.htm","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"BioNTech's Supervisory Board appointed Guido Oelkers, Ph.D., to the Management Board as Chief Executive Officer, succeeding Prof. Ugur Sahin. This is a material executive appointment of a C-suite officer (CEO) at a major biopharmaceutical company, disclosed via press release on August 3, 2026, with an effective date by February 1, 2027. The appointment of a new CEO is a significant governance and leadership event that would affect a reasonable investor's assessment of the company's strategic direction and execution capability.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-03T10:55:38.543901+00:00","company_name":"BioNTech SE","ticker":"BNTX","filing_date":"2026-08-03"}]}